TY - JOUR
T1 - Implications and benefits of the NICE appraisal of pembrolizumab
JO - British Journal of Healthcare Management
PY - 2015/01/01
AU - Danson S
ED -
DO - DOI: 10.12968/bjhc.2015.21.11.506
PB - Mark Allen Group
VL - 21
IS - 11
SP - 506
EP - 508
Y2 - 2025/07/14
ER -